Evidence map›Paper›PMID 40118498›Full record

ArticleJournal for immunotherapy of cancer2025

Osteoarthritis increases the risk of inflammatory arthritis due to immune checkpoint inhibitors associated with tissue-resident memory T cells.

Matthieu Paiola, Daniel M Portnoy, Luke Yi Hao, Shoiab Bukhari, Robert J Winchester, Brian S Henick, Adam Mor, Yevgeniya Gartshteyn

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Matthieu Paiola *Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.ORCID http://orcid.org/0000-0002-3536-861X
Daniel M Portnoy *Department of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.ORCID http://orcid.org/0009-0002-7548-3548
Luke Yi HaoColumbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.ORCID http://orcid.org/0000-0003-4251-3595
Shoiab BukhariDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.ORCID http://orcid.org/0000-0002-1172-7139
Robert J WinchesterDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.ORCID http://orcid.org/0000-0002-7543-8037
Brian S HenickHerbert Irvine Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York, USA.ORCID http://orcid.org/0000-0003-2681-0805
Adam MorDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA am5121@cumc.columbia.edu.ORCID http://orcid.org/0000-0002-1065-2999
Yevgeniya GartshteynDepartment of Medicine, Columbia Center for Translational Immunology, Columbia University Medical Center, New York, New York, USA.ORCID http://orcid.org/0000-0001-5547-4658

Funding

Novel mechanisms regulating PD-1 signaling and functionR01AI125640 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Adam Mor · 2016 to 2026
$4.3M
A systematic approach to uncover the basic mechanisms of checkpoint inhibitor immune related adverse eventsR01AI175498 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Adam Mor, Robert J Winchester · 2023 to 2026
$2.9M
PAG is a novel target in immunotherapyR01AI150597 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2020 to 2024
$2.7M
BD Biosciences InfluxS10OD020056 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SNOECK, HANS-WILLEM E · 2015 to 2015
$600k
Becton Dickinson LSR II Analytical Flow CytometerS10RR027050 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLYNES, RAPHAEL A. · 2011 to 2011
$413k
(PQ8) Predictive biomarkers for the onset of immune-related adverse events associated with PD-1 blockadeR21CA231277 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MOR, ADAM · 2019 to 2020
$361k
NCI NIH HHS R21 CA231277NCRR NIH HHS S10 RR027050NIAID NIH HHS R01 AI125640NIAID NIH HHS R01 AI150597NIAID NIH HHS R01 AI175498NIH HHS S10 OD020056
6 · The paper itself

Abstract

objectiveImmune checkpoint inhibitors (ICIs) have significantly advanced cancer treatment, but they can also lead to immune-related adverse events (irAEs), including inflammatory arthritis. Understanding the risk factors and underlying mechanisms of irAE pathogenesis is crucial for optimal patient management. Increasing evidence suggests that ICI-mediated activation of tissue-resident memory T cells (T

methodsUsing a comprehensive approach, we compared the prevalence of OA in patients with irAE-arthritis to those with irAE non-arthritis and those without irAEs. Additionally, we used advanced immunophenotyping techniques to characterize T-cell populations in the blood and synovial fluid of patients with OA and irAE-arthritis.

resultsOur findings revealed a significantly higher prevalence of OA in patients who developed irAE-arthritis than controls. Furthermore, the multivariable analysis identified OA, body mass index, and smoking as independent risk factors for the development of irAE-arthritis. T

conclusionThis study, the first of its kind, identifies OA as a significant risk factor for irAEarthritis. It reveals a potential mechanism by which ICIs activate PD-1-positive T

Indexed as

ArthritisImmune Checkpoint InhibitorsMemory T CellsOsteoarthritisAgedFemaleHumansMaleMiddle AgedRisk FactorsImmune Checkpoint InhibitorsAutoimmuneImmune Checkpoint InhibitorImmune related adverse event - irAEImmunotherapyT cell

Identifiers

PMID40118498
PMCPMC11931944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.